Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDRX NASDAQ:INTS NASDAQ:RADX NASDAQ:SHOT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$0.85+1.7%$1.05$0.78▼$24.75$30.62M1.171.18 million shs311,362 shsINTSIntensity Therapeutics$0.34-87.1%$0.00$0.26▼$4.97$8.16M3.27530,243 shs73,559 shsRADXRadiopharm Theranostics$4.27-4.0%$4.55$3.50▼$50.82$35.08MN/A18,236 shs28,891 shsSHOTSafety Shot$0.47+5.6%$0.35$0.23▼$1.77$36.87M1.581.70 million shs3.66 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals+1.43%-4.22%+6.99%-40.42%+85,199,900.00%INTSIntensity Therapeutics+2.45%+6.01%+18.37%-81.94%-93.08%RADXRadiopharm Theranostics-4.04%+1.67%-21.51%-0.70%+426,999,900.00%SHOTSafety Shot+5.64%+21.59%+75.63%+5.54%-56.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDRXBiodexa Pharmaceuticals0.203 of 5 stars0.03.00.00.02.00.00.0INTSIntensity Therapeutics2.3555 of 5 stars3.35.00.00.00.60.80.6RADXRadiopharm TheranosticsN/AN/AN/AN/AN/AN/AN/AN/ASHOTSafety ShotN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/AINTSIntensity Therapeutics 2.67Moderate Buy$6.751,914.93% UpsideRADXRadiopharm Theranostics 3.50Strong Buy$12.00181.03% UpsideSHOTSafety Shot 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INTS, RADX, BDRX, and SHOT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025INTSIntensity TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/12/2025RADXRadiopharm TheranosticsThinkEquitySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/1/2025RADXRadiopharm TheranosticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$470K66.24N/AN/A$0.29 per share2.94INTSIntensity TherapeuticsN/AN/AN/AN/A$0.19 per shareN/ARADXRadiopharm TheranosticsN/AN/AN/AN/AN/AN/ASHOTSafety Shot$700K55.64N/AN/A($0.03) per share-15.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$7.32MN/A0.00N/AN/AN/AN/AN/AN/AINTSIntensity Therapeutics-$16.27M-$1.07N/AN/AN/AN/A-527.85%-276.29%N/ARADXRadiopharm TheranosticsN/AN/A0.00∞N/AN/AN/AN/AN/ASHOTSafety Shot-$49.41MN/A0.00∞N/AN/A-1,502.87%-433.74%8/13/2025 (Estimated)Latest INTS, RADX, BDRX, and SHOT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SHOTSafety ShotN/A-$0.08N/A-$0.08N/A$0.04 million5/13/2025Q1 2025INTSIntensity Therapeutics-$0.21-$0.22-$0.01-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AINTSIntensity TherapeuticsN/AN/AN/AN/AN/ARADXRadiopharm TheranosticsN/AN/AN/AN/AN/ASHOTSafety ShotN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa Pharmaceuticals0.011.751.75INTSIntensity Therapeutics0.310.630.63RADXRadiopharm TheranosticsN/AN/AN/ASHOTSafety ShotN/A0.440.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%INTSIntensity Therapeutics3.74%RADXRadiopharm TheranosticsN/ASHOTSafety Shot12.55%Insider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%INTSIntensity Therapeutics17.10%RADXRadiopharm TheranosticsN/ASHOTSafety Shot19.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals2036.54 million36.42 millionNot OptionableINTSIntensity Therapeutics2,02125.07 million20.79 millionNot OptionableRADXRadiopharm TheranosticsN/A7.88 millionN/AN/ASHOTSafety Shot1082.13 million66.42 millionOptionableINTS, RADX, BDRX, and SHOT HeadlinesRecent News About These CompaniesSafety Shot Enters Stock Purchase AgreementJuly 17 at 5:14 PM | tipranks.comRFK Jr.'s Vaccine Panel Wants to Remove Thimerosal From Flu Shots. Is It Actually Toxic?July 16 at 11:50 PM | msn.comSafety Shot Receives 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price RequirementJuly 16 at 8:30 AM | globenewswire.comMichigan football player in Birmingham for training shot multiple times while buying a gunJuly 15 at 11:59 PM | msn.comAustin police looking for robbery victim believed to have been shotJuly 15 at 11:59 PM | msn.comMan hospitalized after being shot in the back in Pittsburgh's Homewood NorthJuly 15 at 11:59 PM | msn.comChurch safety concerns rise, local church hosting a security conference SaturdayJuly 15 at 11:59 PM | msn.comSafety advocate fears his computers were blocked from recording deadly shooting on I-24July 15 at 11:59 PM | msn.com6-year-old Hampton County boy in hospital after being shot, County sheriff stressing gun safetyJuly 15 at 11:59 PM | yahoo.comAt least two men shot in Pittsburgh’s Perry South neighborhoodJuly 15 at 11:59 PM | msn.comInfectious disease expert discusses vaccine safety and aluminum studyJuly 15 at 11:59 PM | yahoo.comEMA Lifts Chikungunya Vaccine Restriction – With CareJuly 12, 2025 | medscape.comMSLU needs 70 volunteers for yellow fever vaccine clinical trialJuly 11, 2025 | msn.comFDA commissioner Dr. Marty Makary on vaccine safety and recommendationsJuly 11, 2025 | msn.comPresentation Before CDC Vaccine Panel Misleads About ThimerosalJuly 10, 2025 | msn.com12-year-old boy shot on 210 Freeway in San Bernardino; suspect arrestedJuly 10, 2025 | msn.comPassenger in SUV, 12, shot in leg on 210 Freeway near San Bernardino; suspect arrestedJuly 10, 2025 | msn.comDeepfake of South African epidemiologist misleads on Covid-19 vaccine safetyJuly 10, 2025 | yahoo.comMan suspected of shooting Philly school safety officer arrested in North JerseyJuly 9, 2025 | phillyvoice.comPMan arrested after Philly school safety officer shot following road rage incident: policeJuly 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendRetail Sales Signal Upside for These 3 Consumer StocksBy Gabriel Osorio-Mazilli | June 22, 2025View Retail Sales Signal Upside for These 3 Consumer Stocks3 International Bank Stocks With Strong DividendsBy Dan Schmidt | June 24, 2025View 3 International Bank Stocks With Strong DividendsBroadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost SharesBy Leo Miller | July 17, 2025View Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost SharesINTS, RADX, BDRX, and SHOT Company DescriptionsBiodexa Pharmaceuticals NASDAQ:BDRX$0.85 +0.01 (+1.67%) Closing price 07/17/2025 03:59 PM EasternExtended Trading$0.85 +0.00 (+0.12%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Intensity Therapeutics NASDAQ:INTSIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.Radiopharm Theranostics NASDAQ:RADX$4.27 -0.18 (-4.04%) As of 07/17/2025 03:59 PM EasternRadiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.Safety Shot NASDAQ:SHOT$0.47 +0.03 (+5.64%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$0.47 -0.01 (-1.73%) As of 04:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Safety Shot, Inc., a wellness and functional beverage company, researches and develops over-the-counter products and intellectual property. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It also develops Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women's sexual wellness; and NoStingz, a jellyfish sting prevention sunscreen. The company sells its products through distributors, retailers, and e-commerce websites. The company was formerly known as Jupiter Wellness, Inc. and changed its name to Safety Shot, Inc. in September 2023. Safety Shot, Inc. was incorporated in 2018 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
